Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

MINT-GABAPENTIN - Health Canada Drug Approval Details

Approvals/Health Canada/MINT-GABAPENTIN

Authorized

STANDARD

MINT-GABAPENTIN

mint pharmaceuticals inc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 35b6df633e966359
Company: mint pharmaceuticals inc
Type: Standard

Approval Details

Approval Id: 35b6df633e966359
Drug Approval Canada Name: MINT-GABAPENTIN
Product Name: MINT-GABAPENTIN
Status: Marketed
Status Date: 2023-08-25
Original Market Date: 2023-08-25
Din: 02408899
Drug Class: Human
Dosage Form: Capsule
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 28:12.92
Atc Original: N02BF01 GABAPENTIN
Atc Name: n 02 bf 01
Aig Number: 0125929003
Company Name: mint pharmaceuticals inc
Company Address: 6575 Davand Drive, Mississauga, Ontario, Canada, L5T 2M3

Active Ingredients

GABAPENTIN

300 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

35b6df633e966359

Type

Standard

Back to Health Canada Approvals